Sign In
Buy ANVS
$1.77
+0.0200 (+1.14%)
At Close: Jun 22, 2026
Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium
09:15am, Monday, 16'th Nov 2020
BERWYN, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other ne
Annovis Bio CEO to Present at Meridian Clinical Trials Summit
06:45am, Monday, 02'nd Nov 2020
BERWYN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other ne
Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer's Disease after COVID-Related Delay
06:45am, Thursday, 29'th Oct 2020
BERWYN, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other ne
David Axelrod, Karl Rove and Matt VanDyke to Speak at TVB Alt Forward 2020 Conference
12:00am, Wednesday, 16'th Sep 2020
TVB’s 2020 Alt Forward Conference will be unlike any before - this year’s conference will be a fully virtual, multi-dimensional experience, taking pla
LD Micro Announces Preliminary List of Presenters for the LD 500
01:00pm, Wednesday, 05'th Aug 2020
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively onlin
We're Not Very Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Rate
11:22am, Tuesday, 28'th Jul 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Stocks To Watch: Big Focus On Big Tech
08:26am, Saturday, 25'th Jul 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
10:45am, Monday, 20'th Jul 2020
BERWYN, Pa., July 20, 2020 -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and.
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, reported that it
Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
10:45am, Tuesday, 16'th Jun 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced
Annovis Bio to Present at the June 2020 Virtual Summer Investor Summit
10:45am, Tuesday, 09'th Jun 2020
BERWYN, Pa., June 09, 2020 -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and.
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
01:00pm, Wednesday, 03'rd Jun 2020
NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9 th -12 th , connecting 47 presenting small and microcap companies with distinguished investors from aroun
Annovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401
10:45am, Tuesday, 02'nd Jun 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced
Annovis Bio 2020 Annual Meeting of Stockholders to Be Held on June 3, 2020
10:45am, Monday, 01'st Jun 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, will hold its 202
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced today
